This article is more than 5 years old. Information may no longer be current.

ODAC recommends accelerated approval for novel iron chelator

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Oncologic Drugs Advisory Committee voted 10-2 in support of accelerated approval for deferiprone (Ferriprox, ApoPharma) for the treatment of patients with iron overload for whom current chelation therapy is inadequate. The issue now goes to the full FDA for approval.

HemOnc Today will have a full story on the decision later today.

Follow HemOncToday.com on Twitter.